These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29461919)

  • 41. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates.
    Monslow MA; Elbashir S; Sullivan NL; Thiriot DS; Ahl P; Smith J; Miller E; Cook J; Cosmi S; Thoryk E; Citron M; Thambi N; Shaw C; Hazuda D; Vora KA
    Vaccine; 2020 Aug; 38(36):5793-5802. PubMed ID: 32703745
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Adjuvanted Recombinant Zoster Vaccine in Adults Aged ≥65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    Dagnew AF; Klein NP; Hervé C; Kalema G; Di Paolo E; Peterson J; Salaun B; Schuind A
    J Infect Dis; 2021 Oct; 224(7):1139-1146. PubMed ID: 32103273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Persistence of Varicella-Zoster Virus Cell-Mediated Immunity After the Administration of a Second Dose of Live Herpes Zoster Vaccine.
    Weinberg A; Popmihajlov Z; Schmader KE; Johnson MJ; Caldas Y; Salazar AT; Canniff J; McCarson BJ; Martin J; Pang L; Levin MJ
    J Infect Dis; 2019 Jan; 219(2):335-338. PubMed ID: 30165651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis.
    Koh JH; Lee J; Kim SH; Kwok SK; Ju JH; Park SH
    J Rheumatol; 2018 Apr; 45(4):465-469. PubMed ID: 29419465
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice.
    Dendouga N; Fochesato M; Lockman L; Mossman S; Giannini SL
    Vaccine; 2012 Apr; 30(20):3126-35. PubMed ID: 22326899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients.
    Chun JY; Kim K; Lee MK; Kang CK; Koh Y; Shin DY; Hong J; Choe PG; Kim NJ; Yoon SS; Park WB; Kim I; Oh MD
    BMC Infect Dis; 2021 Jan; 21(1):117. PubMed ID: 33499826
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥ 70 years: a randomized study of a single dose vs. two different two-dose schedules.
    Vesikari T; Hardt R; Rümke HC; Icardi G; Montero J; Thomas S; Sadorge C; Fiquet A
    Hum Vaccin Immunother; 2013 Apr; 9(4):858-64. PubMed ID: 23319176
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of Varicella-zoster virus-specific cell-mediated immunity by interferon-γ Enzyme-Linked Immunosorbent Assay in adults ≥50 years of age administered a herpes zoster vaccine.
    Yang P; Chen Z; Zhang J; Li W; Zhu C; Qiu P; Quan Y; Cui X; Yuan L; Jiang C
    J Med Virol; 2019 May; 91(5):829-835. PubMed ID: 30613990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
    BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates.
    Li Y; Tian S; Ai Y; Hu Z; Ma C; Fu M; Xu Z; Li Y; Liu S; Zou Y; Zhou Y; Jin J
    Front Immunol; 2024; 15():1419634. PubMed ID: 39081325
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An ODE-based mixed modelling approach for B- and T-cell dynamics induced by Varicella-Zoster Virus vaccines in adults shows higher T-cell proliferation with Shingrix than with Varilrix.
    Keersmaekers N; Ogunjimi B; Van Damme P; Beutels P; Hens N
    Vaccine; 2019 May; 37(19):2537-2553. PubMed ID: 30975567
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, placebo-controlled phase I trial of live, attenuated herpes zoster vaccine in subjects with end-stage renal disease immunized prior to renal transplantation.
    Miller G; Schaefer H; Yoder S; Miller R; Winokur P; Kotloff K; Klassen D; Wierzbicki M; Amegashie C; Edwards K
    Transpl Infect Dis; 2018 Jun; 20(3):e12874. PubMed ID: 29512282
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.
    Stadtmauer EA; Sullivan KM; Marty FM; Dadwal SS; Papanicolaou GA; Shea TC; Mossad SB; Andreadis C; Young JA; Buadi FK; El Idrissi M; Heineman TC; Berkowitz EM
    Blood; 2014 Nov; 124(19):2921-9. PubMed ID: 25237196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Persistence of Varicella-Zoster Virus-Specific Plasma Cells in Adult Human Bone Marrow following Childhood Vaccination.
    Eberhardt CS; Wieland A; Nasti TH; Grifoni A; Wilson E; Schmid DS; Pulendran B; Sette A; Waller EK; Rouphael N; Ahmed R
    J Virol; 2020 Jun; 94(13):. PubMed ID: 32321817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Shingrix for Herpes Zoster: A Review.
    Shah RA; Limmer AL; Nwannunu CE; Patel RR; Mui UN; Tyring SK
    Skin Therapy Lett; 2019 Jul; 24(4):5-7. PubMed ID: 31339679
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative Immune Responses to Licensed Herpes Zoster Vaccines.
    Weinberg A; Kroehl ME; Johnson MJ; Hammes A; Reinhold D; Lang N; Levin MJ
    J Infect Dis; 2018 Sep; 218(suppl_2):S81-S87. PubMed ID: 30247596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.